CIOMS Suspect Adverse Reaction Report

Baxter Healthcare Corporation

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH Day Month Year	2a. AGE	3. SEX	4-6. REACTION ONSET Day Month Year	8-12. CHECK ALL APPROPRIATE TO ADVERSE REACTION
GRO-A	UNITED KINGDOM	GRO-A 1977	28 MONTH	MALE	-- JUL 1979	

7+13. DESCRIBE REACTION(S) (Including relevant tests/lab data)

AIDS (Acquired immunodeficiency syndrome)	MAY1993:Unknown
HIV (HIV test positive)	1983:Unknown
Hepatitis C (Hepatitis C)	07FEB1994:Unknown
Hepatitis B (Hepatitis B)	APR1985:Unknown
Hepatitis A (Hepatitis A)	21NOV1994:Unknown
Low level inhibitor (Factor VIII inhibition)	JUL1979:Unknown

This is a spontaneous case report received by Baxter from Bayer Healthcare (Bayer MFR # 200610135BBE) of a 28-months-old male patient from England who experienced HAV-, HBV-, HCV- and HIV-positivity and low-level factor VIII inhibition following

Cont.

8-12. CHECK ALL APPROPRIATE TO ADVERSE REACTION

- [ ] PATIENT DIED
- [ ] INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- [ ] INVOLVED PERSISTENCE OF SIGNIFICANT DISABILITY OR INCAPACITY
- [X] LIFE THREATENING
- [X] OTHER: Med Significant

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name)

HEMOFIL
(FACTOR VIII (ANTIHAEMOPHILIC FACTOR))
Dose, form, route and frequency: Unknown;UNK;Unknown
Therapy Dates: Unknown
LOT #UNKNOWN

20. DID REACTION ABATE AFTER STOPPING DRUG?

- [ ] YES [ ] NO
- [ ] UNKNOWN [X] NA

15. DAILY DOSE: Unknown

16. ROUTE(S) OF ADMINISTRATION: Unknown

17. INDICATION(S) FOR USE: HEMOPHILIA A

18. THERAPY DATES (FROM/TO): Unknown

19. THERAPY DURATION: Unknown

21. DID REACTION REAPPEAR AFTER REINTRODUCTION?

- [ ] YES [ ] NO
- [ ] UNKNOWN [X] NA

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (Exclude those used to treat reaction)

BPL FACTOR VIII (No Pref. Name)	1992:08APR1995
SANDOGLOBULIN (IMMUNOGLOBULIN HUMAN NORMAL)	09JUN1995:UNKNOWN
REPLENATE (FACTOR VIII (ANTIHAEMOPHILIC FACTOR))	31MAR1995:08NOV1996

Cont.

23. OTHER RELEVANT HISTORY (e.g diagnosis, allergies, pregnancy with last month of period etc.)

Allergy: Unknown
ALLERGIES AGAINST SEPTRIN, METRONIDAZOLE, ERYTHROMYCIN, IMIPENEM AND MAXOLON

Cont.

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER PARENT COMPANY

Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015 USA

LICENSE DETAILS: MAA

24b. MFR. CONTROL NO.: 2007BH000505

24c. DATE RECEIVED BY MANUFACTURER: 18JAN2007

24d. REPORT SOURCE

- [ ] STUDY
- [ ] LITERATURE
- [X] HEALTH PROFESSIONAL
- [ ] REGULATORY AUTHORITY

DATE OF THIS REPORT: 29JAN2007

25a. REPORT TYPE

- [X] INITIAL
- [ ] FOLLOWUP

7+13. DESCRIBE REACTION(S) (Including relevant tests/lab data) (Continued)

treatment with Hemofil and other factor VIII preparations.

This report is part of a class action complaint received by the Bayer Corporate Legal Department on 08-Jul-2004 and forwarded to the Bayer Global Drug Safety-Biological on 02-May-2005. The specific first contact date for this particular case may have been on an unknown later date if the patient was subsequently added to the class action complaint.

This is the narrative provided by Bayer:

Global narrative:

Source of report and patient demography:
This initial spontaneous report is part of a class action complaint received by the Bayer Corporate Legal Department on 08-JUL-2004 and forwarded to Bayer Global Drug Safety-Biological on 02-MAY-2005, referring to a male patient from England. The specific first contact date for this particular case may have been on an unknown later date if the patient was subsequently added to the class action complaint. Plaintiffs contend in these lawsuits that in the 1970's and 1980's they contracted HIV and/or HCV and/or HBV as a result of their use of factor concentrates. Plaintiffs from many international countries and the United States have brought these suits in the US against four US companies that processed plasma derived factor concentrates during the relevant time. All alleged infections occurred potentially from the use of these concentrates, which are no longer manufactured and marketed by Bayer [and for which Bayer no longer has the license]. This case is part of a class action complaint.

Medical and drug history:
Concomitant drugs have been given. For details see section "Concomitant Drugs" at the end of this report.
Risk factors include allergies with Septrin, Metronidazole, Erythromycin, Imipenem and Maxolon.
Suspect drug(s), timing and conditions surrounding the onset of the reaction(s):
The patient received Factor VIII (Bayer) (factor VIII (antihaemophilic factor)), Factor VIII (Cutter) (factor VIII (antihaemophilic factor)) and Factor VIII (Baxter) (factor VIII (antihaemophilic factor)) for severe hemophilia A. Administration dates, lot numbers and total daily doses were not reported. The patient also received Factor VIII (Armour Pharmaceutical Company) (factor VIII (antihaemophilic factor)) in 1980 for approximately 6 years, Factor VIII (Alpha Therapeutic Corporation) (factor VIII (antihaemophilic factor)) in 1986 for a duration of approximately 2 years, Factor VIII (NHS) (factor VIII (antihaemophilic factor)) in 1980-1981, 1987, and 1989-1990, Whole Blood (blood, whole) in 1978 and Cryoprecipitate (plasma protein fraction (human)) in 1979, all for severe hemophilia A. The lot numbers and total daily dose were unknown. The progression of the event(s) and its (their) outcome in the patient: In Jul-1979, the patient who was at that time 2 years of age, experienced LOW LEVEL INHIBITOR considered serious due to important medical event. On an unknown date, the patient experienced HIV considered serious due to life-threatening nature. On an unknown date, the patient experienced HAV, HBV, and HCV considered serious due to important medical event. The outcomes were unknown at the time of the report. The patient comes from a family where there was no previous history of haemophilia. He as diagnosed with Hemophilia A on 17-Jan-1978. The patient developed inhibitors but was a low responder and, therefore, he was able to be treated with normal doses of Factor VIII without rises in inhibitor titre. In June 1979 the patient had no inhibitor, but an inhibitor titre of 0.6 Rizza Biggs units was detected in July 1979. The titre rose to 1.6 Rizza Biggs Units between 08-Jul-1979 and 11-Jul-1979. The inhibitors disappeared by September 1979. April 1985 was the first time that the patient tested positive for Hepatitis B surface and core antibody, but was not positive for Hepatitis B surface antigen. In May 1986, he had slightly raised AST and ALT levels, with intermittent fluctuations. He is HCV seropositive and was informed of this in March 1995. When testing for HIV was introduced, the patient was found to be seropositive and on testing stored samples, the earliest year in which he was found to be seropositive was 1983. The patient was told that he was HIV seropositive in 1989 at which point he was not sexually mature. The patient's first HIV antigen positive test was on 24-Jul-1991 when it was weakly positive by ELISA at 7 pg/ml. This was an isolated finding. He continued to be HIV antigen negative up until 1993. In May 1993 when he had established oral candida, this was used as the date for his AIDS diagnosis. The outcomes were unknown at the time of the report.

Rechallenge information:
For the drugs Factor VIII (Bayer), Factor VIII (Cutter), Factor VIII (Baxter), Factor VIII (Armour Pharmaceutical Company), Factor VIII (Alpha Therapeutic Corporation), Factor VIII (NHS), Whole Blood, and Cryoprecipitate and the diagnoses

The original reporter's clinical assessment:
For the drugs Factor VIII (Bayer), Factor VIII (Cutter), Factor VIII (Baxter), Factor VIII (Armour Pharmaceutical Company), Factor VIII (Alpha Therapeutic Corporation), Factor VIII (NHS), Whole Blood, and Cryoprecipitate no assessment was given.

Bayer Global Comment:
The evaluation of this case is not complete. It is being reported now to meet the legal time limit. A follow-up version will be sent when the evaluation is complete."

Confirmatory Tests:
The patient was iinformed that he is HCV seropositive in March 1995. The earliest year in which he was found to be seropositive was 1983.
April 1985 was the first time that the patient tested positive for Hepatitis B surface and core antibody, but was not positive for Hepatitis B surface antigen. In May 1986, he had slightly raised AST and ALT levels, with intermittent fluctuations.
The patient was told that he was HIV seropositive in 1989. The patient's first HIV antigen positive test was on 24-Jul-1991 when it was weakly positive by ELISA at 7 pg/ml.

The patient tested positive for all HIV antibody tests from 23-AUG-1993 to 20-NOV-1995.
The patient tested negative for Hepatitis A antibody from 23-AUG-1993 to 15-AUG-1994. But then on 21-NOV-1994, the patient tested positive for Hepatitis A antibody.
The patient tested positive for all Hepatitis C antibody tests from 07-FEB-1994 to 20-NOV-1995.
The patient tested negative for all Hepatitis B surface antigen tests from 23-Aug-1993 to 20-Nov-1995.
The patient tested positive for all Hepatitis B core antibody tests from 16-May-1994 to 20-Nov-1995.
The patient tested negative for Hepatitis B surface antibody tests from 23-Aug-1993 to 07-Feb-1994. Starting on 16-May-1994 to 20-Nov-1995, the patient started testing positive and the numbers steadily increased with little fluctation from 30 to 89.

13-Feb-1995 TCC = 350
15-May-1995 TCC = 260

Lab Tests:

Test Name	Coll. Date	Result	Unit	Low Value	High Value
FACTOR VIII ANTIBODIES IN BLOOD	JUL1979	0.6 UNK UNK UNK			
FACTOR VIII ANTIBODIES IN BLOOD	11JUL1979	1.6 UNK UNK UNK			
HIV ANTIBODY	02JUL1994	POS	UNK	UNK	UNK
HIV ANTIBODY	20NOV1995	POS	UNK	UNK	UNK
HIV ANTIGEN	11JAN1993	NEG	UNK	UNK	UNK
HIV ANTIGEN	02JUL1994	NEG	UNK	UNK	UNK
Hepatitis A antibody	15AUG1994	NEG	UNK	UNK	UNK
Hepatitis A antibody	21NOV1994	POS	UNK	UNK	UNK
HEPATITIS B SURFACE ANTIBODY	16MAY1994	30 UNK UNK UNK			
HEPATITIS B SURFACE ANTIBODY	21NOV1994	65 UNK UNK UNK			
HEPATITIS B SURFACE ANTIBODY	15MAY1995	45 UNK UNK UNK			
HEPATITIS B SURFACE ANTIBODY	10AUG1995	92 UNK UNK UNK			
HEPATITIS B SURFACE ANTIBODY	20NOV1995	89 UNK UNK UNK			
Hepatitis B antibody	20NOV1995	POS	UNK	UNK	UNK
Hepatitis B surface antigen	20NOV1995	NEG UNK UNK UNK			
Hepatitis C antibody	02JUL1994	POS	UNK	UNK	UNK
Hepatitis C antibody	20NOV1995	POS	UNK	UNK	UNK
Hemoglobin	23NOV1994	12.0	UNK	UNK	UNK
Hemoglobin	25NOV1994	11.0	UNK	UNK	UNK
Hemoglobin	29NOV1994	11.0	UNK	UNK	UNK
Hemoglobin	05DEC1994	10.0	UNK	UNK	UNK
Hemoglobin	08DEC1994	11.0	UNK	UNK	UNK
Hemoglobin	13DEC1994	9.5	UNK	UNK	UNK
Hemoglobin	29DEC1994	13.0	UNK	UNK	UNK
Hemoglobin	11FEB1995	13.4	UNK	UNK	UNK
Hemoglobin	04MAR1995	14.0	UNK	UNK	UNK
Hemoglobin	06MAR1995	13.5	UNK	UNK	UNK
Hemoglobin	14MAR1995	14.7	UNK	UNK	UNK
Hemoglobin	31MAR1995	12.8	UNK	UNK	UNK
Hemoglobin	15MAY1995	14.6	UNK	UNK	UNK
Hemoglobin	02AUG1995	13.5	UNK	UNK	UNK
Lymphocytes	23NOV1994	0.3	UNK	UNK	UNK
Lymphocytes	25NOV1994	0.2	UNK	UNK	UNK
Lymphocytes	29NOV1994	0.2	UNK	UNK	UNK
Lymphocytes	08DEC1994	0.3	UNK	UNK	UNK
Lymphocytes	13DEC1994	0.5	UNK	UNK	UNK
Lymphocytes	29DEC1994	0.3	UNK	UNK	UNK
Lymphocytes	03JAN1995	0.5	UNK	UNK	UNK
Lymphocytes	11FEB1995	0.3	UNK	UNK	UNK
Lymphocytes	04MAR1995	0.4	UNK	UNK	UNK
Lymphocytes	06MAR1995	0.3	UNK	UNK	UNK
Lymphocytes	09MAR1995	0.4	UNK	UNK	UNK
Lymphocytes	14MAR1995	0.4	UNK	UNK	UNK
Lymphocytes	31MAR1995	0.4	UNK	UNK	UNK
Lymphocytes	15MAY1995	0.5	UNK	UNK	UNK
Neutrophils	23NOV1994	7.9	UNK	UNK	UNK
Neutrophils	25NOV1994	4.5	UNK	UNK	UNK
Neutrophils	29NOV1994	3.4	UNK	UNK	UNK
Neutrophils	05DEC1994	6.5	UNK	UNK	UNK
Neutrophils	08DEC1994	7.2	UNK	UNK	UNK
Neutrophils	13DEC1994	13.6	UNK	UNK	UNK
Neutrophils	29DEC1994	1.3	UNK	UNK	UNK
Neutrophils	03JAN1995	7.6	UNK	UNK	UNK
Neutrophils	08FEB1995	12.9	UNK	UNK	UNK
Neutrophils	11FEB1995	4.0	UNK	UNK	UNK
Neutrophils	13FEB1995	5.5	UNK	UNK	UNK
Neutrophils	04MAR1995	3.9	UNK	UNK	UNK
Neutrophils	06MAR1995	3.0	UNK	UNK	UNK

Neutrophils	09MAR1995	3.1	UNK	UNK	UNK
Neutrophils	15MAY1995	4.5	UNK	UNK	UNK
PLATELET COUNT	23NOV1994	84	UNK	UNK	UNK
PLATELET COUNT	25NOV1994	103	UNK	UNK	UNK
PLATELET COUNT	05DEC1994	132	UNK	UNK	UNK
PLATELET COUNT	08DEC1994	150	UNK	UNK	UNK
PLATELET COUNT	13DEC1994	209	UNK	UNK	UNK
PLATELET COUNT	29DEC1994	140	UNK	UNK	UNK
PLATELET COUNT	03JAN1995	239	UNK	UNK	UNK
PLATELET COUNT	08FEB1995	174	UNK	UNK	UNK
PLATELET COUNT	11FEB1995	176	UNK	UNK	UNK
PLATELET COUNT	13FEB1995	213	UNK	UNK	UNK
PLATELET COUNT	04MAR1995	152	UNK	UNK	UNK
PLATELET COUNT	09MAR1995	156	UNK	UNK	UNK
PLATELET COUNT	14MAR1995	201	UNK	UNK	UNK
PLATELET COUNT	31MAR1995	169	UNK	UNK	UNK
PLATELET COUNT	15MAY1995	169	UNK	UNK	UNK
WBC	23NOV1994	8.5	UNK	UNK	UNK
WBC	29NOV1994	3.9	UNK	UNK	UNK
WBC	05DEC1994	6.8	UNK	UNK	UNK
WBC	08DEC1994	8.4	UNK	UNK	UNK
WBC	13DEC1994	14.3	UNK	UNK	UNK
WBC	29DEC1994	2.2	UNK	UNK	UNK
WBC	03JAN1995	8.4	UNK	UNK	UNK
WBC	08FEB1995	13.9	UNK	UNK	UNK
WBC	11FEB1995	5.1	UNK	UNK	UNK
WBC	13FEB1995	6.5	UNK	UNK	UNK
WBC	31MAR1995	4.0	UNK	UNK	UNK
WBC	15MAY1995	5.7	UNK	UNK	UNK
T4	13FEB1995	20	UNK	UNK	UNK
T4	15MAY1995	10	UNK	UNK	UNK
FACTOR VIII ANTIBODIES IN BLOOD	JUN1979	NEGATIVE UNK UNK UNK			
FACTOR VIII ANTIBODIES IN BLOOD	SEP1979	NEGATIVE UNK UNK UNK			
HIV antigen	24JUL1991	POSITIVE	UNK	UNK	UNK

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name)
FACTOR VIII (BAYER)
(No Pref. Name)
Dose, form, route and frequency
Unknown;UNK;Unknown
LOT #UNKNOWN

Therapy Dates
Unknown

20. DID REACTION ABATE AFTER STOPPING DRUG?
☐ YES ☐ NO ☐ UNKNOWN ☒ NA

15. DAILY DOSE
Unknown

16. ROUTE(S) OF ADMINISTRATION
Unknown

17. INDICATION(S) FOR USE
HEMOPHILIA A

21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
☐ YES ☐ NO ☐ UNKNOWN ☒ NA

18. THERAPY DATES (FROM/TO)
Unknown

19. THERAPY DURATION
Unknown

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name)
FACTOR VIII (CUTTER)
(No Pref. Name)
Dose, form, route and frequency
Unknown;UNK;Unknown
LOT #UNKNOWN

Therapy Dates
Unknown

20. DID REACTION ABATE AFTER STOPPING DRUG?
☐ YES ☐ NO ☐ UNKNOWN ☒ NA

15. DAILY DOSE
Unknown

16. ROUTE(S) OF ADMINISTRATION
Unknown

17. INDICATION(S) FOR USE
HEMOPHILIA A

21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
☐ YES ☐ NO ☐ UNKNOWN ☒ NA

18. THERAPY DATES (FROM/TO)
Unknown

19. THERAPY DURATION
Unknown

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name) FACTOR VIII (ARMOUR PHARMACEUTICAL COMPANY) (No Pref. Name) Dose, form, route and frequency Unknown;UNK;Unknown LOT #UNKNOWN	Therapy Dates 1980:1986	20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☐ UNKNOWN ☒ NA
15. DAILY DOSE Unknown	16. ROUTE(S) OF ADMINISTRATION Unknown	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☐ UNKNOWN ☒ NA
17. INDICATION(S) FOR USE HEMOPHILIA A		
18. THERAPY DATES (FROM/TO) 1980:1986	19. THERAPY DURATION Unknown	

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name) FACTOR VIII (ALPHA THERAPEUTIC CORPORATION) (No Pref. Name) Dose, form, route and frequency Unknown;UNK;Unknown LOT #UNKNOWN	Therapy Dates 1986:1988	20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☐ UNKNOWN ☒ NA
15. DAILY DOSE Unknown	16. ROUTE(S) OF ADMINISTRATION Unknown	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☐ UNKNOWN ☒ NA
17. INDICATION(S) FOR USE HEMOPHILIA A		
18. THERAPY DATES (FROM/TO) 1986:1988	19. THERAPY DURATION Unknown	

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name) FACTOR VIII (NHS) (No Pref. Name) Dose, form, route and frequency Unknown;UNK;Unknown LOT #UNKNOWN Unknown;UNK;Unknown LOT #UNKNOWN Cont.	Therapy Dates 1980:1981 1987:Unknown	20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☐ UNKNOWN ☒ NA
15. DAILY DOSE Unknown	16. ROUTE(S) OF ADMINISTRATION Unknown	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☐ UNKNOWN ☒ NA
17. INDICATION(S) FOR USE HEMOPHILIA A		
18. THERAPY DATES (FROM/TO) 1980:Unknown	19. THERAPY DURATION Unknown	

14. SUSPECT DRUG(S) (Continued) Unknown;UNK;Unknown LOT #UNKNOWN	FACTOR VIII (NHS) 1989:1990	

II. SUSPECT DRUG(S) INFORMATION (Continued)

14. SUSPECT DRUG(S) (include generic name)		20. DID REACTION ABATE AFTER STOPPING DRUG?
BLOOD, WHOLE (BLOOD, WHOLE) Dose, form, route and frequency Unknown;UNK;Unknown LOT #UNKNOWN	Therapy Dates 1978:Unknown	☐ YES ☐ NO ☐ UNKNOWN ☒ NA
15. DAILY DOSE Unknown	16. ROUTE(S) OF ADMINISTRATION Unknown	21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
17. INDICATION(S) FOR USE HEMOPHILIA A		☐ YES ☐ NO ☐ UNKNOWN ☒ NA
18. THERAPY DATES (FROM/TO) 1978:Unknown	19. THERAPY DURATION Unknown	

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)		20. DID REACTION ABATE AFTER STOPPING DRUG?
(PLASMA PROTEIN FRACTION (HUMAN)) (No Pref. Name) Dose, form, route and frequency Unknown;UNK;Unknown LOT #UNKNOWN	Therapy Dates 1979:Unknown	☐ YES ☐ NO ☐ UNKNOWN ☒ NA
15. DAILY DOSE Unknown	16. ROUTE(S) OF ADMINISTRATION Unknown	21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
17. INDICATION(S) FOR USE HEMOPHILIA A		☐ YES ☐ NO ☐ UNKNOWN ☒ NA
18. THERAPY DATES (FROM/TO) 1979:Unknown	19. THERAPY DURATION Unknown	

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (Continued)

FACTOR VIII, 8Y (No Pref. Name) 29AUG1993:29AUG1993

23. OTHER RELEVANT HISTORY (Continued)

Hemophilia A Unknown
SEVERE, DIAGNOSED 17-JAN-1978
Oral candida MAY1993:Unknown

PHARMACOVIGILANCE COMMENTS

Given the paucity of information available in this case, Baxter conservatively assesses this case as related for reporting purposes. This does not necessarily reflect a conclusion by Baxter that the case or information contained within constitutes an admission that the drug caused or contributed to a reported adverse event. The patient had been on many different Factor VIII products in the past. Also there is no information on whether the patient required blood transfusions in the past for any bleeding episodes.
Deborah Lee MD,PhD26Jan2007